PYOGENIC INFECTIONS TREATED WITH NEOMYCIN
- 1 February 1952
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 148 (5) , 334-339
- https://doi.org/10.1001/jama.1952.02930050006002
Abstract
Neomycin, discovered by Waksman and Lechevalier1 in 1949, is an antibiotic which is produced by a strain of Streptomycetes closely related to Streptomyces fradiae. It is a basic compound, heat stable, and freely soluble in water. It does not lose its potency in watery solution or, indeed, in any type of vehicle, which is in striking contrast to many other antibiotics which are available for the topical treatment of cutaneous pyogenic infections. The laboratory work of Waksman and Lechevalier1 and that of other investigators2 indicated that neomycin is bactericidal in vitro against an unusually wide variety of both gram-negative and gram-positive organisms. Furthermore, in their original article on neomycin, Waksman and Lechevalier1 reported that bacterial organisms did not appear to become resistant to the antibiotic, as often happens with streptomycin in particular. Waisbren and Spink,3 Carr and Brown,4 Duncan and others,5 Wolgamot andKeywords
This publication has 5 references indexed in Scilit:
- NEOMYCIN: RESULTS OF CLINICAL USE IN TEN CASESJAMA, 1951
- A CLINICAL APPRAISAL OF NEOMYCINAnnals of Internal Medicine, 1950
- THE EVALUATION OF NEOMYCIN AND OTHER ANTIMICROBIAL AGENTS OF BACTERIAL AND FUNGAL ORIGIN, AND SUBSTANCES FROM HIGHER PLANTSAnnals of the New York Academy of Sciences, 1949
- EVALUATION OF BACITRACIN IN LOCAL TREATMENT OF PYOGENIC INFECTIONSArchives of Dermatology, 1949
- Neomycin, a New Antibiotic Active against Streptomycin-Resistant Bacteria, including Tuberculosis OrganismsScience, 1949